home / stock / avir / avir quote
Last: | $3.7001 |
---|---|
Change Percent: | -0.27% |
Open: | $3.7 |
Close: | $3.71 |
High: | $3.77 |
Low: | $3.695 |
Volume: | 90,959 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.7001 | $3.7 | $3.71 | $3.77 | $3.695 | 90,959 | 04-29-2024 |
$3.71 | $3.71 | $3.71 | $3.72 | $3.6523 | 143,066 | 04-26-2024 |
$3.69 | $3.68 | $3.69 | $3.745 | $3.67 | 174,652 | 04-25-2024 |
$3.7 | $3.71 | $3.7 | $3.735 | $3.68 | 196,516 | 04-24-2024 |
$3.73 | $3.68 | $3.73 | $3.82 | $3.68 | 180,547 | 04-23-2024 |
$3.67 | $3.71 | $3.67 | $3.76 | $3.66 | 345,154 | 04-22-2024 |
$3.72 | $3.69 | $3.72 | $3.77 | $3.6706 | 217,749 | 04-19-2024 |
$3.7 | $3.7 | $3.7 | $3.755 | $3.68 | 267,759 | 04-18-2024 |
$3.71 | $3.73 | $3.71 | $3.785 | $3.71 | 251,669 | 04-17-2024 |
$3.74 | $3.73 | $3.74 | $3.87 | $3.715 | 129,117 | 04-16-2024 |
$3.76 | $3.78 | $3.76 | $3.86 | $3.72 | 219,443 | 04-15-2024 |
$3.76 | $3.82 | $3.76 | $3.89 | $3.73 | 171,066 | 04-12-2024 |
$3.85 | $3.79 | $3.85 | $3.885 | $3.79 | 158,848 | 04-11-2024 |
$3.77 | $3.73 | $3.77 | $3.78 | $3.73 | 266,678 | 04-10-2024 |
$3.81 | $3.78 | $3.81 | $3.85 | $3.77 | 116,700 | 04-09-2024 |
$3.76 | $3.8 | $3.76 | $3.83 | $3.74 | 216,739 | 04-08-2024 |
$3.81 | $3.86 | $3.81 | $3.895 | $3.81 | 138,172 | 04-05-2024 |
$3.85 | $3.95 | $3.85 | $4.01 | $3.83 | 275,374 | 04-04-2024 |
$3.9 | $3.84 | $3.9 | $3.9299 | $3.82 | 165,970 | 04-03-2024 |
$3.87 | $3.93 | $3.87 | $4 | $3.87 | 205,599 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged i...
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting...
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the...